Teleflex, Inc. acquired Semprus BioSciences, a Massachusetts-based biocoatings firm. Semprus offers anti-thrombosis coatings for medical devices.
The deal is valued at $30 million with an opportunity for an additional $50 million in earnouts, per CNNMoney.
MedPlast Inc. has acquired United Plastics Group. The combined entity will have sales of over $250 million. Approximately 60-70% of the company’s revenues will derive from the medical device market, per Plastics News.
MRPC acquired ETI, a liquid silicone molding firm based in Florida. The acquisition brings MRPC a southern hub and 25 employees.
Wisconsin-based MRPC revenues in 2011 were reported as “slightly less than $20 million”.
Theragenics (NYSE:TGX) announced its acquisition of Core Oncology’s prostate brachytherapy customer base. Terms of the deal are an earnout equal to one time the revenue generated from the acquired customers over a one year period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold.
Theragenics paid $3.8 million in cash as prepayment of a portion of the earn-out.
Theragenics (NYSE:TGX) announced its acquisition of Core Oncology’s prostate brachytherapy customer base. Terms of the deal are an earnout equal to one time the revenue generated from the acquired customers over a one year period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold.
Theragenics paid $3.8 million in cash as prepayment of a portion of the earn-out.
AngioDynamics (NASDAQ:ANGO) announced on January 31 its intention to acquire competitor Navilyst Medical for $372 million in cash and stock. Navilyst Medical owners Avista Capital Partners acquired the company from Boston Scientific in 2008. Navilyst’s revenues in 2011 were approximately $149 million. Both AngioDynamics and Navilyst Medical service the peripheral vascular market.
AngioDynamics expects combined revenues of $360 million in FY2013 with $60 million EBITDA.
AngioDynamics (NASDAQ:ANGO) announced on January 31 its intention to acquire competitor Navilyst Medical for $372 million in cash and stock. Navilyst Medical owners Avista Capital Partners acquired the company from Boston Scientific in 2008. Navilyst’s revenues in 2011 were approximately $149 million. Both AngioDynamics and Navilyst Medical service the peripheral vascular market.
AngioDynamics expects combined revenues of $360 million in FY2013 with $60 million EBITDA.
Symmetry Medical (NYSE:SMA) announced on December 29th that it had acquired the surgical instruments business from Codman and Shurtleff, a Johnson & Johnson company. The transaction was done for $165.7 million in cash. The Codman & Shurtleff product line will be incorporated into Symmetry’s hospital-direct business unit.
Symmetry Medical (NYSE:SMA) announced on December 29th that it had acquired the surgical instruments business from Codman and Shurtleff, a Johnson & Johnson company. The transaction was done for $165.7 million in cash. The Codman & Shurtleff product line will be incorporated into Symmetry’s hospital-direct business unit.